RTP Mobile Logo
Proceedings from the 12th Annual Winter Lung Cancer Conference
Released June 2015

Proceedings from a live event featuring traditional didactic faculty presentations and case-based panel discussions focused on all factors that influence multidisciplinary treatment decision-making for lung cancer. Featuring perspectives from Drs A William Blackstock, Julie R Brahmer, David E Gerber, Ramaswamy Govindan, Roy S Herbst, Leora Horn, Mark G Kris, Rogerio C Lilenbaum, Joel W Neal, Harvey I Pass, Charles M Rudin, Mark A Socinski and Everett E Vokes. (Video Program)

CE Disclosures and Faculty Information

  • TARGET AUDIENCE
    This educational activity has been designed to meet the educational needs of medical oncologists, hematology-oncology fellows, nurse practitioners and other allied cancer professionals involved in the treatment of lung cancer.

    OVERVIEW OF ACTIVITY
    Lung cancer is a devastating disease that accounts for approximately 13% of new cancer cases and more cancer-related deaths among both men and women than any other tumor type. In the year 2015, it is estimated that 221,200 individuals will be diagnosed and 158,040 individuals will die from the disease. The plethora of available cytotoxic chemotherapies exhibiting activity in lung cancer has increased substantially over the past several years, and development of new therapeutic strategies beyond cytotoxic chemotherapy has been the focus of extensive recent research and has led to an explosion in lung cancer genetic and biologic knowledge. The advent of these next-generation targeted treatments presents new promise of both efficacy and enhanced safety for patients with lung cancer but also challenges practicing oncologists to appropriately select individuals who may benefit from these agents and to determine how to integrate such therapies, as they become available, into standard lung cancer treatment algorithms.

    This unique educational activity delivers highly applicable current clinical information delving into the personalized management of this challenging disease and provides clinicians with a concise, easy-to-understand resource to facilitate knowledge and application of optimal diagnostic and therapeutic approaches.


    LEARNING OBJECTIVES
    • Develop an evidence-based strategy for the treatment of localized non-small cell lung cancer (NSCLC), exploring the role of (neo)adjuvant systemic therapy.
    • Employ an understanding of personalized medicine to individualize the use of available EGFR inhibitors in the treatment of NSCLC.
    • Describe mechanisms of tumor resistance to EGFR tyrosine kinase inhibitors, and identify therapeutic opportunities to circumvent this process.
    • Communicate the efficacy and safety of crizotinib, ceritinib and other emerging ALK inhibitors to appropriate patients with NSCLC, considering the predictive utility of ALK and ROS1 mutation testing.
    • Devise an evidence-based approach to the selection of induction and maintenance biologic therapy and/or chemotherapy for patients with advanced pan-wild-type NSCLC.
    • Describe emerging data on the efficacy and safety of tumor immunotherapy in lung cancer, and consider this information when counseling patients regarding clinical trial participation.
    • Assess new oncogenic pathways mediating the growth of unique NSCLC tumor subsets, and recall emerging data with experimental agents exploiting these targets.
    • Formulate management strategies for small cell lung cancer, considering the contributory roles of local and systemic therapy.
    • Consider the use of multimodality therapy for appropriate patients with mesothelioma who may potentially be cured with this approach.
    • Recall the design of ongoing clinical trials evaluating novel investigational agents in lung cancer, and counsel appropriately selected patients about availability and participation.
    ACCREDITATION STATEMENT

    CME credit is no longer available for this issue

    CREDIT DESIGNATION STATEMENT

    CME credit is no longer available for this issue

    HOW TO USE THIS CME ACTIVITY
    This activity consists of a video component. The participant should watch the video.

    CME credit is no longer available for this issue

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTY — The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process:


    A William Blackstock, MD
    Professor and Chairman
    Department of Radiation Oncology
    Director, Clinical Research Program
    Comprehensive Cancer Center of Wake Forest University
    Winston-Salem, North Carolina

    No real or apparent conflicts of interest to disclose.

    Julie R Brahmer, MD
    Associate Professor of Oncology
    The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
    Baltimore, Maryland

    Advisory Committee: Bristol-Myers Squibb Company, Merck; Consulting Agreements: Bristol-Myers Squibb Company, Celgene Corporation, Lilly, Merck; Paid Research: AstraZeneca Pharmaceuticals LP; Uncompensated Research: Bristol-Myers Squibb Company.

    David E Gerber, MD
    Associate Professor
    Division of Hematology-Oncology
    Co-Leader, Experimental Therapeutics Program
    Co-Director, Lung Disease Oriented Team
    Harold C Simmons Cancer Center
    University of Texas Southwestern Medical Center
    Dallas, Texas

    Advisory Committee: Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology; Contracted Research: ArQule Inc, Boehringer Ingelheim Pharmaceuticals Inc, Genentech BioOncology, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Peregrine Pharmaceuticals Inc.

    Ramaswamy Govindan, MD
    Professor of Medicine
    Co-Director
    Section of Medical Oncology
    Division of Oncology
    Washington University School of Medicine
    St Louis, Missouri

    Consulting Agreements: GlaxoSmithKline, Merck, Novartis Pharmaceuticals Corporation, Pfizer Inc; Contracted Research: Bayer HealthCare Pharmaceuticals, GlaxoSmithKline, Pfizer Inc.

    Roy S Herbst, MD, PhD
    Ensign Professor of Medicine (Oncology)
    Professor of Pharmacology
    Chief of Medical Oncology
    Director, Thoracic Oncology Research Program
    Associate Director for Translational Research
    Yale Comprehensive Cancer Center
    Yale School of Medicine
    New Haven, Connecticut

    Consulting Agreements: Genentech BioOncology, Lilly, Merck.

    Leora Horn, MD, MSc
    Associate Professor of Medicine
    Assistant Director
    Educator Development Program
    Vanderbilt University Medical Center
    Nashville, Tennessee

    Advisory Committee: Bristol-Myers Squibb Company, Clovis Oncology, Helix BioPharma Corp, Puma Biotechnology Inc; Consulting Agreements: Bayer HealthCare Pharmaceuticals, Merck; Contracted Research: Astellas Scientific and Medical Affairs Inc; Honoraria: Boehringer Ingelheim Pharmaceuticals Inc.

    Mark G Kris, MD
    William and Joy Ruane Chair in Thoracic Oncology
    Attending Physician
    Thoracic Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Advisory Committee: Daiichi Sankyo Inc; Consulting Agreements: Array BioPharma Inc, AstraZeneca Pharmaceuticals LP, Clovis Oncology; Contracted Research: Pfizer Inc, Puma Biotechnology Inc; Other Remunerated Activities: Roche Laboratories Inc.

    Rogerio C Lilenbaum, MD
    Professor of Medicine
    Yale School of Medicine
    Chief Medical Officer
    Smilow Cancer Hospital
    Yale Cancer Center
    New Haven, Connecticut

    Advisory Committee: Celgene Corporation, Genentech BioOncology.

    Joel W Neal, MD, PhD
    Assistant Professor of Medicine
    Division of Oncology
    Stanford Cancer Institute
    Stanford University
    Palo Alto, California

    Contracted Research: ArQule Inc, Genentech BioOncology, Merck.

    Harvey I Pass, MD
    Professor of Surgery and Cardiothoracic Surgery
    Director, Division of Thoracic Surgery
    NYU Langone Medical Center
    New York, New York

    Contracted Research: Genzyme Corporation.

    Charles M Rudin, MD, PhD
    Professor and Chief
    Thoracic Oncology Service
    Memorial Sloan Kettering Cancer Center
    New York, New York

    Consulting Agreements: Abbott Laboratories, Boehringer Ingelheim Pharmaceuticals Inc, GlaxoSmithKline, Merck.

    Mark A Socinski, MD
    Professor of Medicine and Thoracic Surgery
    Director, Lung Cancer Section
    Division of Hematology/Oncology
    Co-Director, UPMC Lung Cancer Center of Excellence
    Co-Director, Lung and Thoracic Malignancies Program
    University of Pittsburgh
    UPMC Cancer Pavilion
    Pittsburgh, Pennsylvania

    Advisory Committee: Bristol-Myers Squibb Company, Lilly, Takeda Oncology; Contracted Research: AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, Lilly, Pfizer Inc, Takeda Oncology; Speakers Bureau: Celgene Corporation, Genentech BioOncology.

    Everett E Vokes, MD
    John E Ultmann Professor
    Chairman, Department of Medicine
    Physician-in-Chief
    University of Chicago Medicine and Biological Sciences
    Chicago, Illinois

    Consulting Agreements: AbbVie Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim Pharmaceuticals Inc, Celgene Corporation, Clovis Oncology, Eisai Inc, GeneCentric Diagnostics Inc, Genentech BioOncology, Merck, Synta Pharmaceuticals Corp, VentiRx Pharmaceuticals Inc.

    MODERATORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Amgen Inc, Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Janssen Biotech Inc, Jazz Pharmaceuticals Inc, Lilly, Medivation Inc, Merck, Myriad Genetic Laboratories Inc, NanoString Technologies, Novartis Pharmaceuticals Corporation, Novocure, Onyx Pharmaceuticals, an Amgen subsidiary, Pharmacyclics Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Sigma-Tau Pharmaceuticals Inc, Sirtex Medical Ltd, Spectrum Pharmaceuticals Inc, Taiho Oncology Inc, Takeda Oncology, Teva Oncology, Tokai Pharmaceuticals Inc and VisionGate Inc.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from Astellas Scientific and Medical Affairs Inc, AstraZeneca Pharmaceuticals LP, Biodesix Inc, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Clovis Oncology, Foundation Medicine, Genentech BioOncology, Lilly, Merck and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio

    Last review date: June 2015
    Expiration date: June 2016

Acknowledge and close

View video: